English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/170802
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Clinical validity of bis(methylthio)gliotoxin for the diagnosis of invasive aspergillosis

AutorVidal-García, Matxalen; Domingo, M.P.; Rueda, Beatriz de; Roc, Lourdes; Delgado, M. Pilar; Revillo, M. José; Pardo, Julián; Gálvez Buerba, Eva Mª ; Rezusta, Antonio
Palabras claveBis(methylthio)gliotoxin
Invasive aspergillosis
Diagnostic accuracy
Galactomannan
Gliotoxin
Fecha de publicación17-dic-2015
EditorSpringer
CitaciónApplied Microbiology and Biotechnology 100: 2327-2334 (2016)
ResumenEarly and accurate diagnosis of invasive aspergillosis (IA) is one of themost critical steps needed to efficiently treat the infection and reduce the high mortality rates that can occur. We have previously found that the Aspergillus spp. secondary metabolite, bis(methylthio)gliotoxin (bmGT), can be detected in the serum from patients with possible/probable IA. Thus, it could be used as a diagnosis marker of the infection. However, there is no data available concerning the sensitivity, specificity and performance of bmGT to detect the infection. Here,we have performed a prospective study comparing bmGT detection with galactomannan (GM), the most frequently used and adopted approach for IA diagnosis, in 357 sera from 90 episodes of patients at risk of IA. Our results, involving 79 patients that finally met inclusion criteria, suggest that bmGT presents higher sensitivity and positive predictive value (PPV) than GM and similar specificity and negative predictive value (NPV). Importantly, the combination of GM and bmGT increased the PPV (100 %) and NPV (97.5 %) of the individual biomarkers, demonstrating its potential utility in empirical antifungal treatment guidance and withdrawal. These results indicate that bmGT could be a good biomarker candidate for IA diagnosis and, in combination with GM, could result in highly specific diagnosis of IA and management of patients at risk of infection.
Versión del editorhttps://doi.org/10.1007/s00253-015-7209-6
URIhttp://hdl.handle.net/10261/170802
DOI10.1007/s00253-015-7209-6
ISSN0175-7598
Aparece en las colecciones: (ICB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
ARCHIVO COMODIN DIGITAL CSIC.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.